A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that usually results in respiratory failure and death. Pirfenidone was approved as the first licensed therapy for IPF in Europe based on phase III trials where patients with a forced vital capacity (FVC) >50% o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2016-07-01
|
| Series: | European Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | http://www.ecrj.net/index.php/ecrj/article/view/32035/47856 |